Navigation Links
Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
Date:6/6/2011

SUNNYVALE, Calif., June 6, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced data from the oral presentation of the Phase IB/II study of the Btk inhibitor, PCI-32765, in chronic lymphocytic leukemia / small cell lymphocytic lymphoma (CLL/SLL) at the 2011 American Society of Clinical Oncology Annual Meeting. The company will also provide a clinical development program update for the Btk Inhibitor, PCI-32765.  The update will include 1) efficacy from the Phase IA trial of PCI-32765 in B-cell malignancies including mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma and 2) a status update for ongoing PCI-32765 clinical studies, and 3) an update on future clinical trials including program expansion opportunities in follicular lymphoma and multiple myeloma.  The company will also provide information on the Non-Hodgkins Lymphoma (NHL) market. An investor conference call to discuss the clinical trial results and other company updates will be hosted today at 4:30pm ET, further information is provided below.  Slide presentations will be posted on the Pharmacyclics website including the ASCO presentation of the Phase IB/II study results and the Investor Relations presentation.  

Data Results from the Phase IB/II Study in CLL/SLL as presented at ASCO

The oral presentation, titled "Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL): Interim results of a Phase Ib/II study" was being presented by John C. Byrd, MD today.  The presentation included interim data from a single-agent, multi-cohort study evaluating PCI-32765 in CLL/SLL patients with relapsed/ refractory disease or with treatment-naive disease who were 65 years of age or older.  A daily oral dose of 420mg was tested
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapies for the treatment ... Timothy E. Morris , chief financial officer  will be ... events are as follows: Mizuho Third Annual ...  The Omni Berkshire Place, New York ...
(Date:4/30/2015)... Calif., April 30, 2015 Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... Fourth quarter and fiscal 2015 overview: ... the fourth quarter, up 33% over last year,s comparable ... year-over-year. , Diluted EPS of $0.50 for the ...
(Date:4/30/2015)... 2015  Tandem Diabetes Care ® , Inc. (NASDAQ: ... t:slim ® and t:flex™ Insulin Pumps, today reported its ... In comparing the first quarter of 2015 to ... percent to $12.3 million from $8.1 million , t:slim ... pumps "Our investment in resources to build the ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24Tandem Diabetes Care Reports First Quarter 2015 Financial Results 2Tandem Diabetes Care Reports First Quarter 2015 Financial Results 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 4Tandem Diabetes Care Reports First Quarter 2015 Financial Results 5Tandem Diabetes Care Reports First Quarter 2015 Financial Results 6
... The North Shore-LIJ Health System Department of Radiation Medicine announced ... the mouth) to participate in a Phase I clinical trial. , ... Subjects must be newly diagnosed and ... with the human papilloma virus (HPV-negative), or, if it is HPV-positive, they ...
... July 23 CRF Health garnered nine awards recently in the ... Health Awards, for their bold, new communications aimed at healthcare professionals involved ... the campaign, Langland, at the awards night in London . , ... Judged by some of the ...
Cached Medicine Technology:Study Seeks Volunteers to Measure Safety of Treatment 'Boost' for Patients with Oropharyngeal Cancer 2CRF Health is Awarded for Getting Closer 2CRF Health is Awarded for Getting Closer 3
(Date:5/3/2015)... (PRWEB) May 03, 2015 Women’s ... their Facebook page. , Their Facebook page ... many services the Practice has, it’s multiple locations, Providers ... Women’s Excellence has a very strong social media presence, ... and You Tube. , Women’s Excellence is the ...
(Date:5/3/2015)... Francisco, CA (PRWEB) May 03, 2015 ... (CFHI), announced it will be awarding the 2015 ... Jennifer Knight and Selemawit Ghebrendrias, are the deserving recipients ... champion for global service, Harris Llewellyn Wofford. The two ... service and passion for global health. , CFHI ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 Indiana Fiber ... Provider announces Bank Computer Services, Inc (BCS) has selected ... BCS’ President states, “The technology, service, and working relationship ... like is the local feel you get with IFN. ... managed company; IFN makes local decisions and operates as ...
(Date:5/3/2015)... 03, 2015 Looking for a ... directly impact your career? The Master of International ... leaders in multinational companies and for professionals seeking ... changing global landscape, differences in culture, religion, government, ... EMIB program develops the global competence and confidence ...
(Date:5/3/2015)... MA (PRWEB) May 03, 2015 SpineFrontier, ... clearance from the FDA to produce and market their ... device can be used in outpatient settings and is ... The alternate posterior approach has been extensively researched and ... 510k approval to use this approach in conjunction with ...
Breaking Medicine News(10 mins):Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3Health News:Bank Computer Services, Inc Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:Bank Computer Services, Inc Selects Indiana Fiber Network, LLC as Fiber Transport Provider 3Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2
... CHICAGO, Oct. 11 Continuing its efforts ... SAVE THE PATIENT, a,not-for-profit patient-focused organization, is hosting ... Network. "Community Health Hotline" will,air Monday, October 15, ... Monday,s program will feature a frank discussion on ...
... simple tool that can improve the effectiveness of communication ... in dramatic improvements in health and safety. , The ... color images of the medication to be taken each ... a patient,s native language if the patient does not ...
... LOUIS, Oct. 11 KV Pharmaceutical Company,(NYSE: KVa/KVb) ... the Special Committee of the Board of Directors ... On October 11, 2007, KV,s Board of ... submitted findings on the internal,investigation of the Company,s ...
... Society volunteers break, national campaign record for free ... Texas, Oct. 11 High temperatures and intense,sunshine ... Hot Air,Balloon Festival to the Women,s Dermatologic Society ... number of free skin,cancer screenings for this 13th ...
... tests are good front-line tests indicators of heart disease, but ... say. , Thirty percent of all women, for example, ... walk for several minutes at a slightly increasing incline with ... say. , So if you are female, I put you ...
... Oct. 11 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) ... quarter of 2007 on Wednesday, October 17, 2007 at ... and Chief Executive,Officer, will lead the call. On the ... the third quarter of 2007. The call will ...
Cached Medicine News:Health News:Patient Empowerment -- Medication Error 2Health News:Improving doctor-patient communication yields significant health benefits 2Health News:Improving doctor-patient communication yields significant health benefits 3Health News:Improving doctor-patient communication yields significant health benefits 4Health News:KV Pharmaceutical Company Reports Results of Special Independent Committee Review of Stock Option Grants 2Health News:KV Pharmaceutical Company Reports Results of Special Independent Committee Review of Stock Option Grants 3Health News:KV Pharmaceutical Company Reports Results of Special Independent Committee Review of Stock Option Grants 4Health News:KV Pharmaceutical Company Reports Results of Special Independent Committee Review of Stock Option Grants 5Health News:KV Pharmaceutical Company Reports Results of Special Independent Committee Review of Stock Option Grants 6Health News:Sun Safety Awareness Reaches New Heights at Plano Hot Air Balloon Festival 2Health News:Sun Safety Awareness Reaches New Heights at Plano Hot Air Balloon Festival 3Health News:Taking the stress out of choosing the right stress test 2Health News:Taking the stress out of choosing the right stress test 3Health News:Amylin Pharmaceuticals to Webcast Third Quarter Results 2
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
... NuSieve 3:1 Agarose is a molecular biology grade, ... for fine resolution of small DNA, RNA, and ... enhance the speed of gel processing and blotting. ... resolution of DNA fragments up to 1,000 bp, ...
... standard gelling temperature, high gel strength agarose ... bp. This Genetic Technology Grade™ (GTG) agarose ... DNA recovered from SeaKem GTG Agarose gels ... GTG Agarose is extensively performance tested to ...
... gel strength, high electrophoretic mobility, and ... is the superior choice for CHEF ... easy to handle at concentrations as ... run times. Low background staining also ...
Medicine Products: